[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563503":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":38,"responsibleParty":54,"collaborators":56,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":18,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":18,"overallStatus":40,"whyStopped":18,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Duke University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Child with cystic fibrosis (CF) on GERD therapy without severe GERD","EXPERIMENTAL","The GSAS will be completed at baseline, GERD therapy will be discontinued, and GSAS will be repeated 12 weeks later.",[13],"Other: Discontinuation of GERD therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Child with cystic fibrosis (CF)","NO_INTERVENTION","The GSAS will be completed at baseline.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Discontinuation of GERD therapy","GERD therapy will be discontinued at time of enrollment.",[9],[25],{"name":26,"affiliation":27,"role":28},"Shatha Yousef","Duke University Hospital","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Yara Salameh, MF","CONTACT","919-684-8111","yara.salameh@duke.edu",{"name":36,"role":32,"phone":18,"phoneExt":18,"email":37},"Shatha Yousef, MD","shatha.yousef@duke.edu",[39],{"facility":27,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Durham","North Carolina","27710","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-78.89862,35.99403,{"lat":50,"lon":49},[53],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},{"type":55,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[57],{"name":58,"class":6},"Cystic Fibrosis Foundation","100563503","gerd-in-children-with-cystic-fibrosis-100563503",false,"NCT06617013","GERD in Children With Cystic Fibrosis","Characteristics of Gastroesophageal Reflux in Children With Cystic Fibrosis","Inclusion Criteria:\n\n* Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.\n* Signed consent\n\nExclusion Criteria:\n\n* Declining to participate in the study or sign consent\n* History of severe GERD per gastroenterology diagnosis and documentation\n* GSAS score \\>80","ALL","2 Years","18 Years",{"count":70,"type":71},20,"ESTIMATED","INTERVENTIONAL",[74],"NA","The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.",[77,78],"GERD in Children","Cystic Fibrosis in Children","2025-12-12",{"date":81,"type":82},"2025-12-19","ACTUAL",{"date":84,"type":82},"2024-10-23",{"date":86,"type":71},"2026-06-30",{"name":5,"class":6},1]